Patrick Oruwari
Psychiatry · Potosi, MONPI 1952396863
Payments from drug & device makers
Across 437 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- AbbVie$1K
- Alkermes, Inc.$903
- Otsuka America Pharmaceutical, Inc.$390
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$382
- Johnson & Johnson$380
- plus $2K from 23 others
What the payments were for
- Food & beverage$7,63098%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 95 | $2,218 |
| AbbVie(2 entities) | 79 | $1,269 |
| Alkermes, Inc. | 39 | $903 |
| Otsuka America Pharmaceutical, Inc. | 25 | $390 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $382 |
| Johnson & Johnson(2 entities) | 26 | $380 |
| Neos Therapeutics, LP | 37 | $354 |
| Harmony Biosciences LLC | 8 | $349 |
| Vanda Pharmaceuticals Inc. | 23 | $287 |
| Supernus Pharmaceuticals, Inc. | 16 | $257 |
| Lundbeck LLC | 13 | $245 |
| Sunovion Pharmaceuticals Inc. | 22 | $212 |
| Braeburn Inc. | 5 | $103 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Novo Nordisk | 2 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Amgen | 2 | $33 |
| Validus Pharmaceuticals LLC | 2 | $27 |
| Abbott | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Indivior Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Acadia Pharmaceuticals Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,432
- INGREZZA$856
- ARISTADA INITIO$358
- VRAYLAR$250
- Wakix$123
How this compares
$7,764 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 125 | $1,059,160 |
| VraylarCariprazine Hcl | 187 | $307,926 |
| Invega SustennaPaliperidone Palmitate | 32 | $115,057 |
| Austedo XrDeutetrabenazine | 13 | $103,213 |
| AristadaAripiprazole Lauroxil | 13 | $44,103 |
| FanaptIloperidone | 25 | $39,429 |
| CaplytaLumateperone Tosylate | 20 | $36,436 |
| RexultiBrexpiprazole | 21 | $29,603 |
| TrintellixVortioxetine Hydrobromide | 61 | $29,457 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $20,571 |
| Aripiprazole | 294 | $18,206 |
| FetzimaLevomilnacipran Hcl | 27 | $17,981 |
| BelsomraSuvorexant | 33 | $14,550 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,150 |
| Paliperidone ErPaliperidone | 46 | $8,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,218 | $1,059,160125 claims |
| AbbVieVraylar, Fetzima | $1,269 | $325,908214 claims |
| Johnson & JohnsonInvega Sustenna | $380 | $115,05732 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $18 | $103,21313 claims |
| Alkermes, Inc.Aristada | $903 | $44,10313 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $287 | $39,42925 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $15 | $38,60785 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $382 | $36,43620 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $390 | $29,60321 claims |
| MerckBelsomra | $14 | $14,55033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Potosi
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
- Vadim BaramSaint Louis$1.9M
- Gary LinkerFordland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.